The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN.alpha.-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN.alpha.-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.